1. Home
  2. BGNE vs GFL Comparison

BGNE vs GFL Comparison

Compare BGNE & GFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BGNE
  • GFL
  • Stock Information
  • Founded
  • BGNE 2010
  • GFL 2007
  • Country
  • BGNE Cayman Islands
  • GFL Canada
  • Employees
  • BGNE N/A
  • GFL N/A
  • Industry
  • BGNE Biotechnology: Pharmaceutical Preparations
  • GFL
  • Sector
  • BGNE Health Care
  • GFL
  • Exchange
  • BGNE Nasdaq
  • GFL Nasdaq
  • Market Cap
  • BGNE 19.2B
  • GFL 18.1B
  • IPO Year
  • BGNE 2016
  • GFL 2020
  • Fundamental
  • Price
  • BGNE $175.87
  • GFL $45.46
  • Analyst Decision
  • BGNE Buy
  • GFL Buy
  • Analyst Count
  • BGNE 8
  • GFL 10
  • Target Price
  • BGNE $253.69
  • GFL $45.80
  • AVG Volume (30 Days)
  • BGNE 476.1K
  • GFL 1.1M
  • Earning Date
  • BGNE 11-12-2024
  • GFL 11-06-2024
  • Dividend Yield
  • BGNE N/A
  • GFL 0.12%
  • EPS Growth
  • BGNE N/A
  • GFL N/A
  • EPS
  • BGNE N/A
  • GFL N/A
  • Revenue
  • BGNE $3,351,304,621.00
  • GFL $5,743,291,755.00
  • Revenue This Year
  • BGNE $969.39
  • GFL $5.50
  • Revenue Next Year
  • BGNE $24.79
  • GFL $6.52
  • P/E Ratio
  • BGNE N/A
  • GFL N/A
  • Revenue Growth
  • BGNE 50.22
  • GFL 4.09
  • 52 Week Low
  • BGNE $126.97
  • GFL $30.57
  • 52 Week High
  • BGNE $248.16
  • GFL $48.87
  • Technical
  • Relative Strength Index (RSI)
  • BGNE 34.52
  • GFL 52.43
  • Support Level
  • BGNE $174.50
  • GFL $44.58
  • Resistance Level
  • BGNE $180.00
  • GFL $46.23
  • Average True Range (ATR)
  • BGNE 6.73
  • GFL 1.20
  • MACD
  • BGNE -2.17
  • GFL -0.30
  • Stochastic Oscillator
  • BGNE 3.24
  • GFL 23.71

About BGNE BeiGene Ltd.

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.

About GFL GFL Environmental Inc. Subordinate voting shares no par value

GFL Environmental Inc is an environmental services company. Its offerings include non-hazardous solid waste management, infrastructure, soil remediation, and liquid waste management services. Its solid waste management business line, which generates the majority of the revenue, consists of the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste. Its Environmental Services business line includes liquid waste and soil remediation. GFL's geographical segments are Canada and the United States. The company derives the majority of its revenue from the United States.

Share on Social Networks: